Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Clinical trial NCT07322783 · RECRUITING

Trial details

NCT number: NCT07322783
Sponsor: Qingdao Central Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Positive Non-small Cell Lung Cancer MET Amplification

Start date: 2025-01-01
Primary completion: 2026-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.